Clinical Trials
Source: CCM
- Score: 31Colorectal Cancer
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- Score: 30Sarcoma Cancers, Brain and Other Nervous System Cancers, Other Cancers, Lymphoma, Kidney Cancer, Leukemia, Liver Cancer, Stomach and Esophagus, Thyroid and Other Endocrine Cancers, Gynecological Cancers, Lung Cancer, Bladder Cancer, Colorectal Cancer, Pediatric Cancers
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
- Score: 29Breast Cancer
An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected With a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)
- Score: 28Lung Cancer
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
- Score: 27Pancreatic Cancer
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
- Score: 26Breast Cancer
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
- Ages18 years and older
- GenderFemale only
- Score: 25Breast Cancer
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
- Score: 24Breast Cancer
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
- Score: 23Lung Cancer
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
- Score: 22Pediatric Cancers
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma